Elizabeth Guancial
Overview
Explore the profile of Elizabeth Guancial including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
234
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vlachou E, Johnson B, Guancial E, Lombardo K, Hoffman-Censits J
Can J Urol
. 2024 Jun;
31(3):11875-11879.
PMID: 38912939
Introduction: Immune checkpoint inhibitors (ICIs) are approved for advanced urothelial cancer alone and as first-line in combination with enfortumab vedotin. Platinum based chemotherapy which is another frontline choice is often...
2.
Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, et al.
Clin Genitourin Cancer
. 2020 Feb;
18(4):e478-e483.
PMID: 32085986
Systemic therapy is the mainstay of treatment for metastatic urothelial carcinoma (UC). Responses to first-line platinum-based therapy tend to be short-lived with potential toxicity. Despite the approval of checkpoint inhibitors,...
3.
Saeed F, Hoerger M, Norton S, Guancial E, Epstein R, Duberstein P
J Pain Symptom Manage
. 2018 Mar;
56(1):1-6.e1.
PMID: 29581034
Context: Men and those with low educational attainment are less likely to receive palliative care. Understanding these disparities is a high priority issue. Objectives: In this study of advanced cancer...
4.
Crist M, Hansen E, Chablani L, Guancial E
Crit Rev Oncol Hematol
. 2017 Dec;
120:151-162.
PMID: 29198329
A systematic review was conducted to illustrate the bleeding risks associated with targeted therapies used in the treatment of metastatic renal cell carcinoma (mRCC). Eligible studies included phase II, III,...
5.
Duberstein P, Chen M, Chapman B, Hoerger M, Saeed F, Guancial E, et al.
Patient Educ Couns
. 2017 Jul;
101(1):113-118.
PMID: 28716485
Objective: Understanding socioeconomic disparities in the care of patients with incurable cancer is a high priority. We hypothesized that patients without a high school education are more likely to believe...
6.
Dineen M, Hansen E, Guancial E, Sievert L, Sahasrabudhe D
J Oncol Pharm Pract
. 2017 Mar;
24(4):314-318.
PMID: 28355968
Abiraterone, a CYP17 inhibitor, blocks androgen biosynthesis in multiple tissue types. In combination with prednisone, it is approved as a first-line treatment for metastatic castration-resistant prostate cancer. We present a...
7.
Meng Y, Bernie H, Weng T, Ling D, Messing E, Guancial E
Rare Tumors
. 2017 Feb;
8(4):6651.
PMID: 28191294
Treatment of locally advanced penile squamous cell carcinoma (pSCC) remains highly controversial secondary to disease rarity and lack of prospective randomized controlled trials. The current mainstays of care are multi-modality...
8.
Loh K, Mondo E, Hansen E, Sievert L, Fung C, Sahasrabudhe D, et al.
Clin Genitourin Cancer
. 2016 Apr;
14(4):e449-52.
PMID: 27102403
No abstract available.
9.
Kilari D, Guancial E, Kim E
World J Clin Oncol
. 2016 Feb;
7(1):106-13.
PMID: 26862494
Platinum (Pt)-based antitumor agents are effective in the treatment of many solid malignancies. However, their efficacy is limited by toxicity and drug resistance. Reduced intracellular Pt accumulation has been consistently...
10.
Kilari D, Iczkowski K, Pandya C, Robin A, Messing E, Guancial E, et al.
Anticancer Res
. 2016 Feb;
36(2):495-501.
PMID: 26851002
Background/aim: Platinum (Pt)-based neoadjuvant chemotherapy (NAC) is the standard-of-care for muscle-invasive bladder cancer (MIBC). However, the survival benefit with NAC is driven by patients with pathological response at cystectomy. Non-responders...